Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium 68 tilmanocept - Navidea Biopharmaceuticals

Next Previous
Drug Profile

Gallium 68 tilmanocept - Navidea Biopharmaceuticals

Alternative Names: [68Ga]Ga-tilmanocept; Ga-68 tilmanocept; Gallium 68 labelled tilmanocept - Navidea Biopharmaceuticals

Latest Information Update: 13 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Navidea Biopharmaceuticals; University of Alabama at Birmingham
  • Developer Navidea Biopharmaceuticals; University Medical Center Utrecht; University of Alabama at Birmingham
  • Class Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Salivary gland cancer; Thyroid cancer
  • No development reported Atherosclerosis

Most Recent Events

  • 13 Feb 2026 Gallium 68 tilmanocept is still in phase-III trials for Thyroid cancer (Diagnosis) in Netherlands
  • 12 Jul 2024 Phase-III clinical trials in Salivary gland cancer (Late-stage disease, Diagnosis) in Netherlands (Intratumoural) (CTIS2024-514233-37-00)
  • 28 Sep 2023 No recent reports of development identified for preclinical development in Atherosclerosis(Diagnosis) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top